Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

bluebird bio

Main focus: Gene therapies and gene editing for the treatment of genetic diseases

Company stage: Clinical

Diseases (gene editing): Haemophilia and other severe genetic diseases

Genome editing tool: megaTAL

Funding stage: Public

Location: Cambridge, MA, USA



Gene editing partnerships: Novo Nordisk

bluebird bio develops novel gene and cancer therapies. The company is developing its proprietary megaTAL gene-editing technology, although it still has to disclose its first pre-clinical candidate derived from this. The company has a collaboration with Novo Nordisk to jointly develop next generation in vivo genome-editing treatments for genetic diseases, including haemophilia.


HashtagBluebird bio

Company: bluebird bio
Search CRISPR Medicine